治疗类风湿性关节炎的新型及新兴疗法。
New and emerging therapies for the treatment of rheumatoid arthritis.
作者信息
Feely Michael G
机构信息
Division of Rheumatology and Immunology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA.
出版信息
Open Access Rheumatol. 2010 Jul 24;2:35-43. doi: 10.2147/oarrr.s6868. eCollection 2010.
Abstract
The introduction of tumor necrosis factor (TNF) inhibitors in the late 1990s significantly changed the therapeutic approach for rheumatoid arthritis (RA). With the approval of subsequent TNF inhibitors as well as other biologic agents effective in the management of RA, the treatment paradigm has become increasingly complex. This review examines the current literature regarding the efficacy and toxicity of these and other new anti-rheumatic therapies and discusses effective therapeutic strategies for their use.
摘要
20世纪90年代末肿瘤坏死因子（TNF）抑制剂的引入显著改变了类风湿关节炎（RA）的治疗方法。随着后续TNF抑制剂以及其他对RA治疗有效的生物制剂获得批准，治疗模式变得越来越复杂。本综述研究了关于这些及其他新型抗风湿疗法的疗效和毒性的当前文献，并讨论了其有效治疗策略。
相似文献
1
New and emerging therapies for the treatment of rheumatoid arthritis.治疗类风湿性关节炎的新型及新兴疗法。
Open Access Rheumatol. 2010 Jul 24;2:35-43. doi: 10.2147/oarrr.s6868. eCollection 2010.
2
Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.英国、法国和德国生物性改善病情抗风湿药在停用依那西普后治疗类风湿关节炎的真实世界疗效
Clin Ther. 2017 Aug;39(8):1618-1627. doi: 10.1016/j.clinthera.2017.06.009. Epub 2017 Jul 17.
3
Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.类风湿关节炎及相关病症中生物制剂感染情况：观察性研究中严重或需住院治疗感染的范围综述
Curr Rheumatol Rep. 2016 Oct;18(10):61. doi: 10.1007/s11926-016-0609-5.
4
The use of biologic therapies in the treatment of rheumatoid arthritis.生物疗法在类风湿关节炎治疗中的应用。
Curr Pharm Biotechnol. 2014;15(6):542-8. doi: 10.2174/138920101506140910150612.
5
A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.一项回顾性队列研究：比较美国成年管理式医疗患者四种常见炎症指征下生物疗法和JAK抑制剂疗法的使用情况及成本
Adv Ther. 2016 Apr;33(4):626-42. doi: 10.1007/s12325-016-0312-y. Epub 2016 Mar 12.
6
Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.医疗保险中类风湿关节炎患者使用生物制剂与住院感染相关的比较风险。
Arthritis Rheumatol. 2016 Jan;68(1):56-66. doi: 10.1002/art.39399.
7
Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas - BiobadaBrasil).巴西使用肿瘤坏死因子阻滞剂的类风湿关节炎患者中结核病的发病率：来自巴西风湿病生物治疗注册中心（巴西生物治疗监测注册中心 - BiobadaBrasil）的数据。
Rev Bras Reumatol Engl Ed. 2017;57 Suppl 2:477-483. doi: 10.1016/j.rbre.2017.05.005. Epub 2017 Jul 22.
8
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
9
Systemic rheumatic diseases: From biological agents to small molecules.系统性风湿病：从生物制剂到小分子药物。
Autoimmun Rev. 2019 Jun;18(6):583-592. doi: 10.1016/j.autrev.2018.12.009. Epub 2019 Apr 5.
10
Comparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic.类风湿关节炎患者从一种生物制剂转换至另一种生物制剂后，不同生物制剂间改善病情抗风湿生物制剂治疗持久性的比较
Rheumatol Ther. 2015 Jun;2(1):59-71. doi: 10.1007/s40744-014-0006-3. Epub 2014 Dec 23.
引用本文的文献
1
Telotristat Etiprate alleviates rheumatoid arthritis by targeting LGALS3 and affecting MAPK signaling.替洛曲酯通过靶向半乳糖凝集素-3（LGALS3）并影响丝裂原活化蛋白激酶（MAPK）信号通路来缓解类风湿性关节炎。
Intractable Rare Dis Res. 2023 Feb;12(1):45-57. doi: 10.5582/irdr.2022.01121.
2
MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2.微小 RNA-101-3p 通过靶向 PTGS2 抑制类风湿关节炎成纤维样滑膜细胞的增殖和炎症。
Biosci Rep. 2020 Jan 31;40(1). doi: 10.1042/BSR20191136.
3
1,25-Dihydroxyvitamin D3 attenuates disease severity and induces synoviocyte apoptosis in a concentration-dependent manner in rats with adjuvant-induced arthritis by inactivating the NF-κB signaling pathway.1,25-二羟维生素 D3 通过抑制 NF-κB 信号通路，以浓度依赖的方式减轻佐剂诱导关节炎大鼠的疾病严重程度并诱导滑膜细胞凋亡。
J Bone Miner Metab. 2019 May;37(3):430-440. doi: 10.1007/s00774-018-0944-x. Epub 2018 Aug 10.
本文引用的文献
1
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.一种口服Syk激酶抑制剂治疗类风湿关节炎：一项针对对生物制剂无反应的活动性类风湿关节炎患者进行的为期三个月的随机、安慰剂对照II期研究。
Arthritis Rheum. 2011 Feb;63(2):337-45. doi: 10.1002/art.30114.
2
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.采用对症治疗、改善病情抗风湿药或生物制剂治疗极早期类风湿关节炎：一项成本效益分析。
Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006.
3
Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.一名类风湿关节炎患者接受利妥昔单抗治疗后发生进行性多灶性白质脑病。
Arthritis Rheum. 2009 Nov;60(11):3225-8. doi: 10.1002/art.24906.
4
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.戈利木单抗，一种人抗肿瘤坏死因子α单克隆抗体，在未使用甲氨蝶呤的活动性类风湿关节炎患者中每四周皮下注射一次：一项戈利木单抗在甲氨蝶呤之前作为早发性类风湿关节炎一线治疗的III期、多中心、随机、双盲、安慰剂对照研究的24周结果。
Arthritis Rheum. 2009 Aug;60(8):2272-83. doi: 10.1002/art.24638.
5
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.接受口服 Janus 激酶（JAK）抑制剂 CP-690,550 治疗的类风湿关节炎患者的疼痛、身体机能和健康状况得到改善：一项随机、双盲、安慰剂对照试验的结果。
Ann Rheum Dis. 2010 Feb;69(2):413-6. doi: 10.1136/ard.2009.108159. Epub 2009 Jul 8.
6
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.一种JAK抑制剂在活动性类风湿关节炎患者中的安全性和有效性：CP-690,550三个剂量水平与安慰剂对照的双盲IIa期试验结果
Arthritis Rheum. 2009 Jul;60(7):1895-905. doi: 10.1002/art.24567.
7
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.肿瘤坏死因子α抑制剂治疗后活动性类风湿关节炎患者使用戈利木单抗（GO-AFTER研究）：一项多中心、随机、双盲、安慰剂对照的III期试验
Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26.
8
Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.类风湿关节炎、银屑病关节炎和强直性脊柱炎的真实世界抗肿瘤坏死因子治疗：基于改善健康评估问卷所需治疗人数的成本效益
J Rheumatol. 2009 Jul;36(7):1421-8. doi: 10.3899/jrheum.081122. Epub 2009 Jun 1.
9
Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).肿瘤坏死因子拮抗剂治疗类风湿关节炎患者增加其劳动力参与率：潜在的显著长期间接成本收益（来自基于人群的登记处的数据）。
Ann Rheum Dis. 2010 Jan;69(1):126-31. doi: 10.1136/ard.2009.108035.
10
Dealing with immunogenicity of biologicals: assessment and clinical relevance.生物制品的免疫原性处理：评估及临床相关性
Curr Opin Rheumatol. 2009 May;21(3):211-5. doi: 10.1097/bor.0b013e328329ed8b.
Zotero 插件